Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial - Martin, M; Holmes, F A; Ejlertsen, B (Lancet Oncol, 2017)